drugset
drugset / Trial / NCT02534909

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT02534909 ↗

Phase 2 Completed 10 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Timeline

Start
2015-09-09
Primary completion
2022-05-24
Completion
2022-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Iptacopan Small molecule 200 mg Oral
Subject tesidolumab Monoclonal antibody 20 mg/kg Intravenous

Indications

paroxysmal nocturnal hemoglobinuria